CLINICAL AND PHARMACEUTICAL ANALYSIS OF APPLICATION OF ANTIHYPERTENSIVE MEDICATIONS IN PATIENTS WITH ARTERIAL HYPERTENSION IN THE REPUBLIC OF UZBEKISTAN (4-9)

Архив в PDF формате
Дата публикации статьи в журнале: 2019/11/13
Название журнала: Восточно Европейский Научный Журнал, Выпуск: 50, Том: 2, Страницы в выпуске: 4-9
Автор: Moroz V.A.
, National University of Pharmacy, doctor of medical sciences
Автор: Timchenko Y.V.
, National University of Pharmacy, candidate of medical science
Анотация: In order to determine the degree of compliance of the ongoing medicinal treatment of patients with arterial hypertension with current international recommendations, the prescription of medications in 136 patients of one of the regional multidisciplinary medical centers of Uzbekistan was retrospectively evaluated. Based on the analysis of patient histories an unreasonably underestimated frequency of use of beta-blockers (54% of the examined), ACE inhibitors (47.9%) and diuretics (32.3%) were found. In 27.4% of cases, the dosage of beta-blockers was insufficient, and in 15% of cases, an overdose of medications was noted. Calcium channel blockers were used quite widely, but in 7.4% of cases, their use was found to be not following the indications for patients with heart failure. Side effects were observed in 25.3% of patients, which in many cases were predictable and easily eliminated. It is concluded that in order to increase the rationality of arterial hypertension therapy, taking into account the concomitant pathology, a more complete consideration of modern recommendations on the use of antihypertensive medications and a thorough analysis of ongoing pharmacotherapy, as well as the need for a clinical pharmacist to participate in the treatment process are required.
Ключевые слова: arterial hypertension   antihypertensive medication   modern руководства   beta-blockers   calcium channel blockers   ACE inhibitors   angiotensin II receptor blockers   angiotensin II receptor blockers   diuretics  
Данные для цитирования: Moroz V.A. , Timchenko Y.V. , . CLINICAL AND PHARMACEUTICAL ANALYSIS OF APPLICATION OF ANTIHYPERTENSIVE MEDICATIONS IN PATIENTS WITH ARTERIAL HYPERTENSION IN THE REPUBLIC OF UZBEKISTAN (4-9). Восточно Европейский Научный Журнал. Медицинские науки. 2019/11/13; 50(2):4-9.

Список литературы: 1. Ettehad D., Connor A.E., Kiran A. et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and metaanalysis. Lancet. 2016, V.387, No.10022, pp. 957967. 2. Ionov M.V., Zvartau N.E., Konradi A.O. First look at new 2018 joint ESH/ESC Guidelines on diagnosis and management of hypertension. Arterial’naya Gipertenziya [Arterial Hypertension], 2018, V.24, No.3, pp. 351-358. 3. Aziz M., Yadav K.S. Pathogenesis of Atherosclerosis. Med Clin Rev., 2016, No.2, pp. 6-22. 4. Singh R.B., Mengi S.A., Xu Y-J. et al. Pathogenesis of atherosclerosis: A multifactorial process. Exp Clin Cardiol., 2002, V.7, No.1, pp. 40-53. 5. Williams B., Mancia G., Spiering W. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2018, V.39, No.33, pp. 3021-3104. 6. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels (9th ed.). Little, Brown & Co, Boston, 1994, pp. 253-256. 7. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, V.34, No.28, pp. 2159-2219. 8. Thomopoulos C., Parati G., Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs - overview and metaanalyses. J Hypertens., 2015, V.33, No.7, pp. 13211341. 9. Bradley H.A., Wiyonge C.S., Volmink V.A. et al. How strong is the evidence for use of beta-blockers as first line therapy for hypertension? J Hypertens., 2006, V.24, No.8, pp. 2131-2141. 10. Thomopoulos C., Parati G., Zanchetti A. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens., 2017, V.35, No.11, pp. 2150-2160. 11. Moroz V.A. Clinical and pharmaceutical analysis of beta-blocker usage in Al-Sader hospital (Iraq). Visnyk UMSA: Aktual’ní problemi suchasnoi medicini [Actual Problems of the Modern Medicine], 2013, V.13, No.2, pp. 134-137. 12. Velasco A., Solow E., Price A. et al. Differential effects of nebivolol vs. metoprolol on microvascular function in hypertensive humans. Am J Physiol Heart Circ Physiol., 2016, V.311, No. 1, pp. 118-124. 13. Almeman A.A., Beshir Y.A., Aldosary A.H. Comparison of the Effects of Metoprolol and Bisoprolol on Lipid and Glucose Profiles in Cardiovascular Patients. Curr Drug Saf., 2019, V.14, No.1, pp. 27-30. 14. Zanchetti A. Calcium channel blockers in hypertension. In: Hypertension, a companion to Braunwald Heart Disease / Ed. H.R. Black, W.J. Elliott. Elsevier. 2012, Chapt.22, pp. 204-218. 15. Daskalopoulou S.S., Rabi D.M., Zarnke K.B. et al. The 2015 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension. Canadian Journal of Cardiology, 2015, V.31, No.5, pp. 549-568. 16. Costanzo P., Perrone-Filardi P., Petretta M. et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175634 patients. J Hypertens., 2009, V.27, No.8, pp. 1136-1151. 17. Luders S., Schrader J., Berger J. et al. The PHARAO Study: prevention of hypertension with the angiotensin converting enzyme inhibitor ramipril in patients with high normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League. J Hypertens., 2008, V.26, No.4, pp. 1487-1496. 18. Shunan F., Jiqing Y., Xue D. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events in patients with diabetes and overt nephropathy: a metaanalysis of randomised controlled trials. J Renin Angiotensin Aldosterone Syst., 2018, V.19, No.4, pp. 1-9. 19. van Vark L.C., Bertrand M., Akkerhuis K.M.et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensinaldosterone system inhibitors involving 158998 patients. Eur Heart J., 2012, V.33, No.8, pp. 2088-2097. 20. Tamargo J., Segura J., Ruilope L.M. Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. Expert Opin Pharmacother., 2014, V.15, No.4, pp. 527-547. 21. Kobalava D.Z., Shavarova K.E. Clinical Features of Arterial Hypertension in the Elderly and Senile Age and the Rationale for Using the Combination of Amlodipine/Indapamide-retard. Kardiologiia [Cardiology], 2017, V.57, No.8, pp. 60-70.